Startseite Kongressberichte & Archiv ASCO Annual Meeting 2017 Head & Neck Cancer Highlights Statements Sacha Rothschild, Jean Bourhis & Marco Merlano

PD Dr. Sacha Rothschild, USB, Basel

Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979):

 

ASCO2017Sacha Rothschild - locoregionally advanced nasopharyngeal carcinoma from Oncoletter on Vimeo.

Prof. Jean Bourhis, CHUV

Interview about the data of Noronha et al. presented at ASCO “Phase III randomized trial comparing weekly versus 3-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer”.

 

Prof. Marco Merlano, Italy

Explains the ADCC mechanism, why this mechanism is important regarding cetuximab and the greatest potential for EGFR antibodies in head and neck tumors:

 


 

ASCO2017Marco Merlano - Cetuximab in Head&Neck Tumors from Oncoletter on Vimeo.